Phase I Results From A Phase I/Ii Study Of Orteronel, An Oral, Investigational, Nonsteroidal 17,20-Lyase Inhibitor, With Docetaxel And Prednisone (Dp) In Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

Daniel Peter Petrylak,Jitendra G. Gandhi,William R. Clark,Elisabeth I. Heath,Jianqing Lin,William K. Oh,David B. Agus,Omer Kucuk,Susan Moran, Jingyuan Wang,Michael Bargfrede,Glenn Liu

JOURNAL OF CLINICAL ONCOLOGY（2012）

引用 1|浏览19

暂无评分

摘要

4656 Background: The investigational agent orteronel (ortl, TAK-700) is a selective 17,20-lyase inhibitor that blocks androgen production. Since DP is standard chemotherapy in mCRPC, this phase 1/2...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要